OBR Daily Commentary


CLL & Mantle Cell Lymphoma: Immediate Impact of 2014 ASCO Presentations on Clinical Practice

Read Article arrow

Jan Heybroek (Posted: July 11, 2014)


Stephanie, thank you for your insightful comment. You were correct and we have re-analyzed the data to find there was an inconsistency. The graphs and conclusions related to ibrutinib have been updated in this blog. You can download the full report on our website, link provided in the blog. Thanks!



Add Comment 2 Comment(s)